1.Analysis of Disease Burden and Attributable Risk Factors of Early-onset Female Breast Cancer in China and Globally from 1990 to 2021
Danqi HUANG ; Min YANG ; Wei XIONG ; Jingyi LIU ; Wanqing CHEN ; Jingbo ZHAI ; Jiang LI
Medical Journal of Peking Union Medical College Hospital 2025;16(3):777-784
To analyze the disease burden, temporal trends, and attributable risk factors of early-onset female breast cancer (EOBC) in China and globally from 1990 to 2021. Data on the absolute numbers and crude rates of incidence, mortality, and disability-adjusted life years (DALYs) for EOBC (diagnosis age < 50 years) in China and globally were extracted from the Global Burden of Disease (GBD) 2021 database. Attributable DALY proportions for five risk factors (smoking, alcohol use, physical inactivity, high red meat consumption, elevated fasting plasma glucose) and all combined risk factors were obtained. Joinpoint regression analysis was performed to assess temporal trends in age-standardized rates, quantified by annual percentage change (APC) and average annual percentage change (AAPC). From 1990 to 2021, age-standardized incidence rates of EOBC increased significantly in both China (AAPC=2.25%) and globally (AAPC=0.64%; pairwise comparison, China's age-standardized EOBC incidence is rising rapidly and approaching global levels, while mortality and DALY rates have increased over the past decade, underscoring persistent challenges in disease control. Future efforts should prioritize expanding the coverage of breast cancer screening programs, optimizing screening protocols, and enhancing public awareness of cancer prevention to mitigate the growing burden of EOBC in China.
2.Circulating immunological transcriptomic profile identifies DDX3Y and USP9Y on the Y chromosome as promising biomarkers for predicting response to programmed death 1/programmed death ligand 1 blockade.
Liting YOU ; Zhaodan XIN ; Feifei NA ; Min CHEN ; Yang WEN ; Jin LI ; Jiajia SONG ; Ling BAI ; Jianzhao ZHAI ; Xiaohan ZHOU ; Binwu YING ; Juan ZHOU
Chinese Medical Journal 2025;138(3):364-366
3.Buzhong Yiqi Decoction alleviates immune injury of autoimmune thyroiditis in NOD.H-2~(h4)mice via c GAS-STING signaling pathway.
Yi-Ran CHEN ; Lan-Ting WANG ; Qing-Yang LIU ; Zhao-Han ZHAI ; Shou-Xin JU ; Xue-Ying CHEN ; Zi-Yu LIU ; Xiao YANG ; Tian-Shu GAO ; Zhi-Min WANG
China Journal of Chinese Materia Medica 2025;50(7):1872-1880
This study aims to explore the effects of Buzhong Yiqi Decoction(BYD) on the cyclic guanosine monophosphate-adenosine monophosphate synthase(cGAS)-stimulator of interferon genes(STING) signaling pathway in the mouse model of autoimmune thyroiditis(AIT) and the mechanism of BYD in alleviating the immune injury. Forty-eight NOD.H-2~(h4) mice were assigned into normal, model, low-, medium-, and high-dose BYD, and selenium yeast tablets groups(n=8). Mice of 8 weeks old were treated with 0.05% sodium iodide solution for 8 weeks for the modeling of AIT and then administrated with corresponding drugs by gavage for 8 weeks before sampling. High performance liquid chromatography was employed to measure the astragaloside Ⅳ content in BYD. Hematoxylin-eosin staining was employed to observe the pathological changes in the mouse thyroid tissue. Enzyme-linked immunosorbent assay was employed to measure the serum levels of thyroid peroxidase antibody(TPO-Ab), thyroglobulin antibody(TgAb), and interferon-γ(IFN-γ). Flow cytometry was employed to detect the distribution of T cell subsets in the spleen. The immunohistochemical method was used to detect the expression of cGAS, STING, TANK-binding kinase 1(TBK1), and interferon regulatory factor 3(IRF3). Real-time PCR and Western blot were employed to determine the mRNA and protein levels, respectively, of markers related to the cGAS-STING signaling pathway in the thyroid tissue. The results showed that the content of astragaloside Ⅳ in BYD was(7.06±0.08) mg·mL~(-1). Compared with the normal group, the model group showed disrupted structures of thyroid follicular epithelial cells, massive infiltration of lymphocytes, and elevated levels of TgAb and TPO-Ab. Compared with the model group, the four treatment groups showed intact epithelial cells, reduced lymphocyte infiltration, and lowered levels of TgAb and TPO-Ab. Compared with the normal group, the model group showed increases in the proportions of Th1 and Th17 cells, a decrease in the proportion of Th2 cells, and an increase in the IFN-γ level. Compared with the model group, the four treatment groups presented decreased proportions of Th1 and Th17 cells and lowered levels of IFN-γ, and the medium-dose BYD group showed an increase in the proportion of Th2 cells. Compared with the normal group, the modeling up-regulated the mRNA levels of cGAS, STING, TBK1, and IRF3 and the protein levels of cGAS, p-STING, p-TBK1, and p-IRF3. Compared with the model group, the four treatment groups showed reduced levels of cGAS, STING, TBK1, and IRF3-positive products, down-regulated mRNA levels of cGAS, STING, and TBK1, and down-regulated protein levels of cGAS and p-STING. The high-dose BYD group showed down-regulations in the mRNA level of IRF3 and the protein levels of p-TBK1 and p-IRF3. The above results indicate that BYD can repair the imbalance of T cell subsets, alleviate immune injury, and reduce thyroid lymphocyte infiltration in AIT mice by inhibiting the cGAS-STING signaling pathway.
Animals
;
Drugs, Chinese Herbal/administration & dosage*
;
Signal Transduction/drug effects*
;
Thyroiditis, Autoimmune/metabolism*
;
Mice
;
Membrane Proteins/metabolism*
;
Mice, Inbred NOD
;
Humans
;
Female
;
Nucleotidyltransferases/metabolism*
;
Male
;
Disease Models, Animal
4.Analysis of Real-World Outcomes in Patients with Acute Promyelocytic Leukemia Treated with Arsenic Trioxide and All-trans Retinoic Acid without Chemotherapy.
Jia WANG ; Qian-Shan TAO ; Yi DONG ; Zhi-Min ZHAI
Journal of Experimental Hematology 2025;33(5):1254-1261
OBJECTIVE:
To investigate the effect of non-chemotherapy strategy of retinoic acid (ATRA) combined with arsenic trioxide (ATO) on the survival of patients with acute promyelocytic leukemia (APL).
METHODS:
The data of APL patients with complete information diagnosed in the hematology department of our hospital from June 2009 to November 2024 were retrospective analyzed. All patients in the non-CHT group received ATRA-ATO induction, consolidation and maintenance therapy. Patients in the CHT group received ATRA-ATO+chemotherapy induction therapy, followed by 3 cycles of ATRA-ATO+CHT consolidation therapy and 6-10 cycles of ATRA-ATO maintenance therapy. The primary endpoint was event-free survival (EFS). Secondary endpoints included overall survival (OS), remission rate, differentiation syndrome (DS) and safety.
RESULTS:
There were 182 patients with APL and 15 patients with early death (ED), accounting for 8.24%, which was related to age and risk stratification. There was no significant difference in remission rate between the non-CHT group and the CHT group (P =0.486). As of February 2025, the median follow-up time of patients was 39.5 months. The EFS of the non-CHT group was significantly better than that of the CHT group (P =0.038). There was no significant difference in OS between the two groups (P =0.442). Subgroup analysis showed that EFS in the non-CHT was longer in standard-risk patients (P =0.012). There was no significant difference in EFS (P =0.585) and OS (P =0.473) between the CHT and non-CHT groups in high-risk patients. The incidence of mild DS was 23.6% in the non-CHT group and 23.1% in the CHT group, respectively, with no statistically significant difference(P =0.937). Compared with CHT group, the incidence of serious adverse events was lower in the non-CHT group.
CONCLUSION
The non-chemotherapy regimen of ATRA combined with ATO is a feasible method to cure APL patients.
Humans
;
Leukemia, Promyelocytic, Acute/drug therapy*
;
Arsenic Trioxide/therapeutic use*
;
Tretinoin/administration & dosage*
;
Retrospective Studies
;
Female
;
Treatment Outcome
;
Male
;
Adult
;
Antineoplastic Combined Chemotherapy Protocols/therapeutic use*
;
Middle Aged
;
Remission Induction
5.Efficacy and Safety of Diagnostic-Driven Therapy for Invasive Fungal Disease in Patients with Myeloid Hematologic Malignancies.
Hui XIAO ; Fan WU ; Ying PAN ; Fu-Run AN ; Zhi-Min ZHAI
Journal of Experimental Hematology 2025;33(5):1524-1528
OBJECTIVE:
To investigate the efficacy and safety of diagnostic-driven therapy for invasive fungal disease(IFD) in patients with myeloid hematologic malignancies.
METHODS:
A retrospective analysis was conducted on the clinical data of 91 patients with myeloid hematologic malignancies who received diagnostic-driven therapy for IFD at the Second Hospital of Anhui Medical University from January 1, 2020 to December 31, 2023. The patients were divided into two groups based on medication: 44 patients in the caspofungin group and 47 patients in the voriconazole group. The clinical efficacy and adverse reactions of the two groups were compared and analyzed.
RESULTS:
The overall response rates in the caspofungin and voriconazole groups were 67.4% and 60.0%, respectively. Among patients who transitioned to diagnostic-driven therapy following prophylactic or empirical treatment with triazole antifungal agents, the response rate of the caspofungin group was significantly higher than that of the voriconazole group (76.9% vs 35.3%, P <0.05). A total of 9 patients in both groups experienced adverse reactions, and no grade III or higher adverse reactions occurred. The incidence of grade I-II adverse reactions in the caspofungin group was lower than in the voriconazole group (2.3% vs 17.0%, P <0.05).
CONCLUSION
In patients with myeloid hematologic malignancies, caspofungin and voriconazole demonstrate comparable clinical efficacy in diagnostic-driven therapy for IFD, but caspofungin is associated with a lower incidence of adverse reactions. Caspofungin exhibits significant effectiveness when initiating diagnostic-driven therapy after prophylactic or empirical treatment with broad-spectrum triazole antifungal agents.
Humans
;
Retrospective Studies
;
Hematologic Neoplasms/complications*
;
Antifungal Agents/therapeutic use*
;
Voriconazole/therapeutic use*
;
Caspofungin/therapeutic use*
;
Invasive Fungal Infections/diagnosis*
;
Male
;
Female
;
Mycoses/drug therapy*
;
Middle Aged
;
Treatment Outcome
;
Aged
;
Adult
6.A preliminary analysis of the clinical characteristics of patients with temperature-sensitive temporomandibular joint disorder syndrome.
Yifan HU ; Bowen MA ; Xiaoting ZHAI ; Xinyu XU ; Yihan WANG ; Hongbo LI ; Min HU ; Hongchen LIU ; Hua JIANG
West China Journal of Stomatology 2025;43(2):269-274
OBJECTIVES:
This study aims to analyze the clinical symptoms and imaging manifestations in patients with temporomandibular disorder syndrome (TMD), who are sensitive to sudden temperature drop.
METHODS:
One hundred and nineteen patients with TMD who attended the Department of Stomatology of the First Medical Center of Chinese People's Liberation Army General Hospital from December 2022 to December 2023 were included, including 44 males and 75 females, with a mean age of 32.4±13.7 years.The questionnaire was used to determine whether they were sensitive to temperature drop, and the TMD patients were divided into a temperature plunge-sensitive group and a temperature drop insensitive group. The clinical symptoms and imaging manifestations of patients in the two groups were observed. SPSS 25.0 was used for statistical analysis.
RESULTS:
There was no statistically significant difference between the gender and age of patients in the temperature plunge-sensitive group (50 patients) and the insensitivity group (69 patients) (P>0.05). The percentage of patients with pain was slightly higher in the temperature plunge-sensitive group [86.0% (43/50)] than in the insensitive group [68.1% (47/69)], and the difference was statistically significant (χ2=5.031, P=0.025), while the differences in joint murmur and mouth opening limitation between the two groups were not statistically significant. A total of 238 lateral joints were detected in both groups, the percentage of osteoarthropathic imaging changes was significantly higher in the temperature plunge-sensitive group [82.0% (82/100)] than in the insensitive group [53.6% (74/138)] (χ2=20.675, P<0.001). Magnetic imaging showed that the percentage of joint effusion was higher in patients in the temperature plunge-sensitive group [66.0% (33/50)] than in the insensitive group [42.0% (29/69)], and the difference was statistically significant (χ2=5.602, P=0.018).
CONCLUSIONS
TMD patients with maxillofacial pain symptoms, joint effusions, and abnormal imaging of osteoarticular structures are more likely to be sensitive to sudden temperature drops.
Humans
;
Male
;
Female
;
Adult
;
Temporomandibular Joint Disorders/diagnosis*
;
Surveys and Questionnaires
;
Middle Aged
;
Young Adult
;
Temperature
;
Adolescent
7.GPR40 novel agonist SZZ15-11 regulates glucolipid metabolic disorders in spontaneous type 2 diabetic KKAy mice
Lei LEI ; Jia-yu ZHAI ; Tian ZHOU ; Quan LIU ; Shuai-nan LIU ; Cai-na LI ; Hui CAO ; Cun-yu FENG ; Min WU ; Lei-lei CHEN ; Li-ran LEI ; Xuan PAN ; Zhan-zhu LIU ; Yi HUAN ; Zhu-fang SHEN
Acta Pharmaceutica Sinica 2024;59(10):2782-2790
G protein-coupled receptor (GPR) 40, as one of GPRs family, plays a potential role in regulating glucose and lipid metabolism. To study the effect of GPR40 novel agonist SZZ15-11 on hyperglycemia and hyperlipidemia and its potential mechanism, spontaneous type 2 diabetic KKAy mice, human hepatocellular carcinoma HepG2 cells and murine mature adipocyte 3T3-L1 cells were used. KKAy mice were divided into four groups, vehicle group, TAK group, SZZ (50 mg·kg-1) group and SZZ (100 mg·kg-1) group, with oral gavage of 0.5% sodium carboxymethylcellulose (CMC), 50 mg·kg-1 TAK875, 50 and 100 mg·kg-1 SZZ15-11 respectively for 45 days. Fasting blood glucose, blood triglyceride (TG) and total cholesterol (TC), non-fasting blood glucose were tested. Oral glucose tolerance test and insulin tolerance test were executed. Blood insulin and glucagon were measured
8.Protective effect of hesperetin on renal ischemia-reperfusion injury in rats through Nrf2-ARE pathway
Xin-Duo ZHAI ; Min JIN ; Yu LIU
The Chinese Journal of Clinical Pharmacology 2024;40(12):1803-1807
Objective To study the effect of hesperetin(HSP)on renal ischemia-reperfusion injury(RIRI)in rats and its mechanism.Methods Fifty male SD rats were randomly divided into five groups:sham group,model group(renal ischemia-reperfusion injury I/R),HSP pretreatment(HSP+I/R)group,all-trans retinoic acid pretreatment(ATRA+I/R)group,HSP and ATRA pretreatment(HSP+ATRA+1/R)group.Each group had 10 rats.The sham group only exposed both kidneys by opening the abdominal cavity.In other groups,the RIRI model was established by occluding the bilateral renal pedicles for 45 min,followed by reperfusion for 24 h.Hematoxylin-eosin staining(HE)was used to ascertain the extent of kidney injury.The microplate method was used to measure serum creatinine(Scr)levels,while the urease method was used to measure blood urea nitrogen(BUN)levels.Enzyme-linked immunosorbent assay(ELISA)was used to detect the contents of interleukin-6(IL-6),interleukin-1β(IL-1 β)and tumor necrosis factor-α(TNF-α)in the serum.The kit method was used to examine the levels of superoxide dismutase(SOD),glutathione(GSH),malondialdehyde(MDA)and catalase(CAT)in kidney tissue.The Western blot analysis was conducted to detect the expression of nuclear factor erythroid 2 related factor 2(Nrf2)and its downstream antioxidant proteins heme oxygenase-1(HO-1)and quinone oxide reductase 1(NQO1)in renal tissues.Results The scores for renal tubule damage in sham,I/R and HSP+I/R groups were 0.20±0.45,4.20±0.84 and 2.40±0.55;Scr contents were(55.52±11.23),(207.10±19.22)and(105.60±18.11)μmol·L-1;IL-6 contents were(33.66±6.83),(172.50±8.09)and(105.40±10.03)pg·mL-1.The SOD levels in sham,I/R,HSP+I/R,ATRA+I/R and HSP+ATRA+I/R groups were(57.04±3.44),(37.29±3.60),(51.61±9.41),(32.55±5.58)and(37.40±3.66)U·mg·prot-1;the relative expression levels of Nrf2 were 0.37±0.24,0.57±0.28,1.31±0.34,0.44±0.17 and 0.77±0.25;the relative expression levels of HO-1 protein were 0.26±0.14,0.57±0.30,1.32±0.61,0.53±0.28 and 0.67±0.50.There was significant difference in renal tubule damage score,Scr,IL-6 and SOD indexes in I/R group compared to sham group(P<0.05,P<0.01).The above indexes were statistically significant between HSP+I/R group and I/R group(P<0.05,P<0.01).Conclusion The activation of HSP may stimulate the Nrf2-antioxidant response element(ARE)pathway,enhance the expression of downstream antioxidant proteins,mitigate the renal damage caused by oxidative stress,and ultimately improve RIRI.
9.Healthcare-associated infection and pathogen spectrum in neonatal inten-sive care unit:a 5-year single-center study
Yan-Min LI ; Rui-Min ZHANG ; Li-Li PING ; Li-Na ZHAI ; Xiao-Li ZHANG ; Jun-Yue HAN
Chinese Journal of Infection Control 2024;23(2):195-200
Objective To understand the spectrum and changes of pathogens causing healthcare-associated infec-tion(HAI)in neonatal intensive care unit(NICU).Methods Clinical medical records of neonates with HAI in a hospital from January 2018 to December 2022 were collected,spectrum of pathogens causing HAI were and analyzed retrospectively.Results A total of 7 597 hospitalized neonates were investigated,and 240 of whom had 263 cases of HAI,with an HAI incidence of 3.16%and healthcare-associated case infection incidence of 3.46%.96 cases(36.50%)were bloodstream infection,70(26.62%)were respiratory system infection,and 57(21.67%)were in-fection without clear sites.A total of 170 pathogens were detected from specimens,78(45.88%)of which were Gram-positive bacteria,with Staphylococcus spp.accounting for the highest proportion,78(45.88%)were Gram-negative bacteria,mainly Klebsiella pneumoniae,and 14(8.24%)were fungi.The detection rate of Gram-negative bacteria showed an upward trend from 2018 to 2022(P<0.01).Conclusion The majority of HAI in NICU is bloodstream infection.In recent years,the detection rate of Gram-negative bacteria has been increasing year by year,and it is necessary to streng-then the prevention and control of HAI in clinical practice.
10.Protein expression and clinical significance of KCTD8 gene in ductal carcinoma of the breast
Ying-Ge LIU ; Hui-Jie YANG ; Xiao-Yu ZHAI ; Ji-Min HE ; Hong-Chao LI ; Ying-Li ZHANG
Chinese Journal of Current Advances in General Surgery 2024;27(2):117-121
Objective:To investigate the expression of KCTD8 gene in breast ductal carcinoma and its correlation with clinical factors and prognosis.Methods:Immunohistochemistry technology(IHC)were employed to detect protein expression levels of KCTD8 in 27 pairs of breast ductal carci-noma and its paired adjacent tissues.Analyzing the correlation between changes in KCTD8 expres-sion of protein and clinical factors using statistical techniques.RNA expression and methylation data of breast cancer(including intraductal cancer)were analysed from TCGA database.Result:The pro-tein expression of KCTD8 gene in 27 pairs of breast ductal carcinoma tissues showed a decreasing trend compared to adjacent tissues(P<0.05),and the decreased expression level of protein was cor-related with the tumor size of patients(P<0.05).The analysis results of the TCGA database indicate that the expression and hypemethylation of KCTD 8 gene in breast cancer(including intraductal can-cer)tissues affected the prognosis of patients.Conclusion:The reduced protein expression level of KCTD8 gene in breast ductal carcinoma may be involved in the development and affect the prog-nosis of patients.

Result Analysis
Print
Save
E-mail